

Tarlton Properties Announces Intersect ENT Lease Expansion and Extension

Posted on January 6, 2015

MENLO PARK, Calif. (Jan. 6, 2015) – Tarlton Properties, Inc. (TPI), a commercial property development and asset manager, announced today Intersect ENT has signed a long-term lease expansion for an additional 18,000 square feet at 1555 Adams Drive in Menlo Park, Calif. Intersect ENT now has a long-term lease on the entire building, totaling more than 50,000 square feet.

Intersect ENT (NASDAQ: XENT) is a publicly traded company dedicated to improving the quality of life for patients with ear, nose and throat conditions. Intersect ENT's mission is to advance clinically proven therapy solutions that enable ear, nose, and throat (ENT) physicians to solve clinical challenges and improve the quality of life for patients. Intersect ENT's initial focus is chronic sinusitis, a condition that affects one out of eight adults in the U.S. and has a greater impact on quality of life than congestive heart failure or chronic back pain. Intersect ENT currently holds more than 25 issued U.S. patents and more than 85 patents and pending applications worldwide.

"We are excited to be in a position for robust growth in our company," said Lisa Earnhardt, president and CEO of Intersect ENT. "Our home in Menlo Park provides us with the space, amenities and location to continue to advance our mission of advancing treatment options for patients afflicted with chronic sinusitis."

"Intersect ENT is a strong leader in the growing life sciences community and, as such, we are proud they are thriving in our biotech and life sciences campus in Menlo Park," said John Tarlton, president and CEO of Tarlton Properties.

About Tarlton Properties

Tarlton Properties, Inc., (TPI) founded in 1980 and headquartered in Menlo Park, Calif., provides commercial property development, redevelopment, construction management, asset and [property management services ranging from brokerage to receiverships as well as innovative and creative investment opportunities in select properties. TPI's full development capabilities are illustrated by its largest project, the award-winning, 50-acre, 900,000-square-foot Menlo Business Park. TPI has developed and redeveloped approximately 4.5 million square feet in the area, both as a principal and for other owners, including 1.5 million square feet of REO properties for institutional clients. For detailed information, visit: www.tarlton.com

About Intersect ENT

Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two drug-eluting implants, PROPEL and PROPEL mini, clinically proven to improve surgical outcomes for patients with chronic sinusitis undergoing ethmoid sinus surgery. In addition, Intersect ENT is developing new drug-eluting implants designed to provide ENT physicians with even more customized options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers. Visit www.intersectent.com

